New Approaches to SCLC Therapy: From the Laboratory to the Clinic

John T. Poirier, Julie George, Taofeek K. Owonikoko, Anton Berns, Elisabeth Brambilla, Lauren A. Byers, David Carbone, Huanhuan J. Chen, Camilla L. Christensen, Caroline Dive, Anna F. Farago, Ramaswamy Govindan, Christine Hann, Matthew D. Hellmann, Leora Horn, Jane E. Johnson, Young S. Ju, Sumin Kang, Mark Krasnow, James LeeSe Hoon Lee, Jonathan Lehman, Benjamin Lok, Christine Lovly, David MacPherson, David McFadden, John Minna, Matthew Oser, Keunchil Park, Kwon Sik Park, Yves Pommier, Vito Quaranta, Neal Ready, Julien Sage, Giorgio Scagliotti, Martin L. Sos, Kate D. Sutherland, William D. Travis, Christopher R. Vakoc, Sarah J. Wait, Ignacio Wistuba, Kwok Kin Wong, Hua Zhang, Jillian Daigneault, Jacinta Wiens, Charles M. Rudin, Trudy G. Oliver*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

111 Scopus citations


The outcomes of patients with SCLC have not yet been substantially impacted by the revolution in precision oncology, primarily owing to a paucity of genetic alterations in actionable driver oncogenes. Nevertheless, systemic therapies that include immunotherapy are beginning to show promise in the clinic. Although, these results are encouraging, many patients do not respond to, or rapidly recur after, current regimens, necessitating alternative or complementary therapeutic strategies. In this review, we discuss ongoing investigations into the pathobiology of this recalcitrant cancer and the therapeutic vulnerabilities that are exposed by the disease state. Included within this discussion, is a snapshot of the current biomarker and clinical trial landscapes for SCLC. Finally, we identify key knowledge gaps that should be addressed to advance the field in pursuit of reduced SCLC mortality. This review largely summarizes work presented at the Third Biennial International Association for the Study of Lung Cancer SCLC Meeting.

Original languageEnglish
Pages (from-to)520-540
Number of pages21
JournalJournal of Thoracic Oncology
Issue number4
StatePublished - Apr 2020


  • ASCL1
  • Gene mutations
  • Neuroendocrine
  • SCLC
  • Therapy


Dive into the research topics of 'New Approaches to SCLC Therapy: From the Laboratory to the Clinic'. Together they form a unique fingerprint.

Cite this